Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)

Adrien Eshraghi, Mayank Aranke, Richard Salvi, Dalian Ding, John K.M. Coleman, Emre Ocak, Rahul Mittal, Thomas Meyer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a growing interest in the auditory community to develop novel prophylactic and therapeutic drugs to prevent permanent sensorineural hearing loss following acute cochlear injury. The jun-N-terminal protein kinase (JNK) pathway plays a crucial role in acute sensory hearing loss. Blocking the JNK pathway using the cell-penetrating peptide D-JNKI-1 (AM-111/brimapitide) has shown promise as both a prophylactic and therapeutic agent for acute cochlear injury. A number of pre-clinical and clinical studies have determined the impact of D-JNKI-1 on acute sensorineural hearing loss. Given the inner-ear selective therapeutic profile, local route of administration, and ability to diffuse across cellular membranes rapidly using both active and passive transport makes D-JNK-1 a promising oto-protective drug. In this review article, we discuss the application of D-JNKI-1 in various auditory disorders as well as its pharmacological properties and distribution in the cochlea.

Original languageEnglish (US)
JournalHearing Research
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cell-Penetrating Peptides
Cochlea
Sensorineural Hearing Loss
Protective Agents
Active Biological Transport
Wounds and Injuries
Inner Ear
Hearing Loss
Therapeutics
Pharmacology
Membranes
D-JNKI-1
Pharmaceutical Preparations
protein kinase N

Keywords

  • Acute sensorineural hearing loss
  • AM-111
  • Brimapitide
  • D-JNKI-1
  • JNK pathway
  • Noise trauma

ASJC Scopus subject areas

  • Sensory Systems

Cite this

Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111). / Eshraghi, Adrien; Aranke, Mayank; Salvi, Richard; Ding, Dalian; Coleman, John K.M.; Ocak, Emre; Mittal, Rahul; Meyer, Thomas.

In: Hearing Research, 01.01.2018.

Research output: Contribution to journalArticle

Eshraghi, Adrien ; Aranke, Mayank ; Salvi, Richard ; Ding, Dalian ; Coleman, John K.M. ; Ocak, Emre ; Mittal, Rahul ; Meyer, Thomas. / Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111). In: Hearing Research. 2018.
@article{2ab44b690350416697222b318cfa35d7,
title = "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)",
abstract = "There is a growing interest in the auditory community to develop novel prophylactic and therapeutic drugs to prevent permanent sensorineural hearing loss following acute cochlear injury. The jun-N-terminal protein kinase (JNK) pathway plays a crucial role in acute sensory hearing loss. Blocking the JNK pathway using the cell-penetrating peptide D-JNKI-1 (AM-111/brimapitide) has shown promise as both a prophylactic and therapeutic agent for acute cochlear injury. A number of pre-clinical and clinical studies have determined the impact of D-JNKI-1 on acute sensorineural hearing loss. Given the inner-ear selective therapeutic profile, local route of administration, and ability to diffuse across cellular membranes rapidly using both active and passive transport makes D-JNK-1 a promising oto-protective drug. In this review article, we discuss the application of D-JNKI-1 in various auditory disorders as well as its pharmacological properties and distribution in the cochlea.",
keywords = "Acute sensorineural hearing loss, AM-111, Brimapitide, D-JNKI-1, JNK pathway, Noise trauma",
author = "Adrien Eshraghi and Mayank Aranke and Richard Salvi and Dalian Ding and Coleman, {John K.M.} and Emre Ocak and Rahul Mittal and Thomas Meyer",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.heares.2018.03.003",
language = "English (US)",
journal = "Hearing Research",
issn = "0378-5955",
publisher = "Elsevier",

}

TY - JOUR

T1 - Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)

AU - Eshraghi, Adrien

AU - Aranke, Mayank

AU - Salvi, Richard

AU - Ding, Dalian

AU - Coleman, John K.M.

AU - Ocak, Emre

AU - Mittal, Rahul

AU - Meyer, Thomas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There is a growing interest in the auditory community to develop novel prophylactic and therapeutic drugs to prevent permanent sensorineural hearing loss following acute cochlear injury. The jun-N-terminal protein kinase (JNK) pathway plays a crucial role in acute sensory hearing loss. Blocking the JNK pathway using the cell-penetrating peptide D-JNKI-1 (AM-111/brimapitide) has shown promise as both a prophylactic and therapeutic agent for acute cochlear injury. A number of pre-clinical and clinical studies have determined the impact of D-JNKI-1 on acute sensorineural hearing loss. Given the inner-ear selective therapeutic profile, local route of administration, and ability to diffuse across cellular membranes rapidly using both active and passive transport makes D-JNK-1 a promising oto-protective drug. In this review article, we discuss the application of D-JNKI-1 in various auditory disorders as well as its pharmacological properties and distribution in the cochlea.

AB - There is a growing interest in the auditory community to develop novel prophylactic and therapeutic drugs to prevent permanent sensorineural hearing loss following acute cochlear injury. The jun-N-terminal protein kinase (JNK) pathway plays a crucial role in acute sensory hearing loss. Blocking the JNK pathway using the cell-penetrating peptide D-JNKI-1 (AM-111/brimapitide) has shown promise as both a prophylactic and therapeutic agent for acute cochlear injury. A number of pre-clinical and clinical studies have determined the impact of D-JNKI-1 on acute sensorineural hearing loss. Given the inner-ear selective therapeutic profile, local route of administration, and ability to diffuse across cellular membranes rapidly using both active and passive transport makes D-JNK-1 a promising oto-protective drug. In this review article, we discuss the application of D-JNKI-1 in various auditory disorders as well as its pharmacological properties and distribution in the cochlea.

KW - Acute sensorineural hearing loss

KW - AM-111

KW - Brimapitide

KW - D-JNKI-1

KW - JNK pathway

KW - Noise trauma

UR - http://www.scopus.com/inward/record.url?scp=85044338795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044338795&partnerID=8YFLogxK

U2 - 10.1016/j.heares.2018.03.003

DO - 10.1016/j.heares.2018.03.003

M3 - Article

C2 - 29573879

AN - SCOPUS:85044338795

JO - Hearing Research

JF - Hearing Research

SN - 0378-5955

ER -